Overnight stimulation: a new rescue strategy for deep brain stimulation-induced bradykinesia in dystonia?
Objective: We report the serendipity case of overnight stimulation for the management of stimulation-induced bradykinesia in two patients with generalized dystonia and clinically-effective pallidal deep…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits
Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…Identification and clinical characterization of GBA variants in the Luxembourg Parkinson’s Study
Objective: Assess the entire set of variants in the glucocerebrosidase (GBA) gene by long-read sequencing in the Luxembourg Parkinson’s study (LuxPARK) and characterize genotype-phenotype correlations…Coexistence of Parkinson’s Disease and Myasthenia Gravis: Disease Characteristics and Confusion
Objective: In order to alert clinicians to the possibility of the coexistence of the two diseases and optimize the management of both conditions. Background: Parkinson’s…The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)
Objective: To identify the effect of rasagiline on nocturnal hypokinesia based on Nocturnal Hypokinesia Questionnaire (NHQ). Background: Nocturnal hypokinesia refers to the difficulty or the…Scaling the Roche Digital Health Technology Platform to Assess Disease Severity and Progression in Individuals with Parkinson’s Disease
Objective: Here we present the development of a novel platform to deliver the Roche Parkinson’s Disease (PD) Mobile Application to researchers to actively measure motor…Compound heterozygous PANK2 variants in two unrelated kindreds with atypical PKAN
Objective: To describe two unrelated individuals with progressive, late-onset Pantothenate kinase-associated neurodegeneration (PKAN) and a common missense variant in the PANK2 gene Background: Neurodegeneration with Brain-Iron Accumulation…What research participants want to know: Feedback from participants in an observational study of Parkinson’s disease
Objective: To compare participant feedback regarding clinical assessments, patient-reported outcomes (PROs), and digital technologies provided in individual research reports in an observational study of Parkinson’s…
- « Previous Page
- 1
- …
- 654
- 655
- 656
- 657
- 658
- …
- 1734
- Next Page »